{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:39:23Z","timestamp":1769099963908,"version":"3.49.0"},"reference-count":28,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["PB-PG-0816-20011"],"award-info":[{"award-number":["PB-PG-0816-20011"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Intracerebral haemorrhage (ICH) can be devastating and is a common cause of death and disability worldwide. Pre-ICH antiplatelet drug use is associated with a 27% relative increase in 1\u2009month case fatality compared with patients not using antithrombotic drugs. We aim to assess the feasibility of conducting a randomised controlled testing the safety and efficacy of desmopressin for patients with antiplatelet-associated ICH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We aim to include 50 patients within 24\u2009hours of spontaneous ICH onset, associated with oral antiplatelet drug(s) use in at least the preceding 7\u2009days. Patients will be randomised (1:1) to receive intravenous desmopressin 20\u2009\u00b5g in 50 mL sodium chloride 0.9% infused over 20\u2009min or matching placebo. We will mask participants, relatives and outcome assessors to treatment allocation. Feasibility outcomes include proportion of patients approached being randomised, number of patients receiving allocated treatment, rate of recruitment and adherence to treatment and follow-up. Secondary outcomes include change in ICH volume at 24\u2009hours; hyponatraemia at 24\u2009hours, length of hospital stay, discharge destination, early death less than 28 days, death or dependency at day 90, death up to day 90, serious adverse events (including thromboembolic events) up to day 90; disability (Barthel index, day 90), quality of life (EuroQol 5D (EQ-5D), day 90), cognition (telephone mini-mental state examination day 90) and health economic assessment (EQ-5D).<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH) trial received ethical approval from the East Midlands\u2014Nottingham 2 research ethics committee (18\/EM\/0184). The DASH trial is funded by National Institute for Health and Care Research RfPB grant: PB-PG-0816-20011. Trial results will be published in a peer reviewed academic journal and disseminated through academic conferences and through patient stroke support groups. Reporting will be in compliance with Consolidated Standards of Reporting Trials recommendations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration numbers<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03696121\">NCT03696121<\/jats:ext-link>;<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT67038373\">NCT67038373<\/jats:ext-link>; EudraCT 2018-001904-12.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-037555","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:44:17Z","timestamp":1680716657000},"page":"e037555","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03696121","registry":"10.18810\/clinical-trials-gov","type":"preResults"},{"clinical-trial-number":"nct67038373","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-5616","authenticated-orcid":false,"given":"Michael J R","family":"Desborough","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rustam","family":"Al-Shahi Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Havard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Dineen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J","family":"Coats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trish","family":"Hepburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M","family":"Bath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Sprigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"2023040221342476000_10.11.e037555.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31012-1"},{"key":"2023040221342476000_10.11.e037555.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32335-3"},{"key":"2023040221342476000_10.11.e037555.3","unstructured":"Royal College of Physicians . Sentinal stroke national audit programme (SSNAP). Royal College of Physicians, 2016."},{"key":"2023040221342476000_10.11.e037555.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70107-2"},{"key":"2023040221342476000_10.11.e037555.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f735e5"},{"key":"2023040221342476000_10.11.e037555.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214609"},{"key":"2023040221342476000_10.11.e037555.7","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.552919"},{"key":"2023040221342476000_10.11.e037555.8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(18)30253-9","article-title":"Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data","volume":"17","author":"Al-Shahi Salman","year":"2018","journal-title":"Lancet Neurol"},{"key":"2023040221342476000_10.11.e037555.9","article-title":"Haemostatic therapies for acute spontaneous intracerebral haemorrhage","volume":"4","author":"Al-Shahi Salman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2023040221342476000_10.11.e037555.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01695.x"},{"key":"2023040221342476000_10.11.e037555.11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13064"},{"key":"2023040221342476000_10.11.e037555.12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14423"},{"key":"2023040221342476000_10.11.e037555.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608422104"},{"key":"2023040221342476000_10.11.e037555.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-497123"},{"key":"2023040221342476000_10.11.e037555.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-015-0222-x"},{"key":"2023040221342476000_10.11.e037555.16","unstructured":"Royal College of Physicians . Intercollegiate stroke Working Party. National clinical guideline for stroke. London, UK: Royal College of Physicians, 2016."},{"key":"2023040221342476000_10.11.e037555.17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jth.13576","article-title":"Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Desborough","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2023040221342476000_10.11.e037555.18","article-title":"Desmopressin use for minimising perioperative blood transfusion","volume":"7","author":"Desborough","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2023040221342476000_10.11.e037555.19","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.006061"},{"key":"2023040221342476000_10.11.e037555.20","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/298767","article-title":"Desmopressin acetate in intracranial haemorrhage","volume":"2014","author":"Kapapa","year":"2014","journal-title":"Neurol Res Int"},{"key":"2023040221342476000_10.11.e037555.21","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/CCM.0000000000004021","article-title":"Retrospective assessment of desmopressin effectiveness and safety in patients with Antiplatelet-Associated intracranial hemorrhage","volume":"47","author":"Feldman","year":"2019","journal-title":"Crit Care Med"},{"key":"2023040221342476000_10.11.e037555.22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jocn.2019.05.032","article-title":"Cohort analysis of desmopressin effect on hematoma expansion in patients with spontaneous intracerebral hemorrhage and documented pre-ictus antiplatelet use","volume":"66","author":"Schmidt","year":"2019","journal-title":"J Clin Neurosci"},{"key":"2023040221342476000_10.11.e037555.23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1366"},{"key":"2023040221342476000_10.11.e037555.24","article-title":"Remote assessment of platelet function in patients with acute stroke or transient ischaemic attack","volume":"2017","author":"Bath","year":"2017","journal-title":"Stroke Res Treat"},{"key":"2023040221342476000_10.11.e037555.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869"},{"key":"2023040221342476000_10.11.e037555.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"2023040221342476000_10.11.e037555.27","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(18)31033-X","article-title":"Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial","volume":"391","author":"Sprigg","year":"2018","journal-title":"Lancet"},{"key":"2023040221342476000_10.11.e037555.28","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (patch): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"The Lancet"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-037555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:44:32Z","timestamp":1680716672000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-037555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,10]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-037555"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-037555","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}